Business Context and Reporting Period
This Form 8-K was filed by Lisata Therapeutics, Inc. on May 3, 2026. The filing reports the entry into a material definitive agreement regarding a previously announced merger with Kuva Labs Inc. (Parent) and its subsidiary, Kuva Acquisition Corp. (Purchaser).
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The only specific financial figure disclosed relates to transaction expenses:
- Expense Payment: Parent has agreed to pay up to $1.1 million in aggregate expenses of the Company until the commencement of the tender offer.
The filing text does not provide a clear value for the Company's current cash position, debt levels, or liquidity runway, though these are noted as risks in the forward-looking statements section.
Material Changes
The primary material change is the amendment to the Agreement and Plan of Merger dated March 6, 2026:
- Extension of Tender Offer Deadline: The date by which the Purchaser is obligated to commence the tender offer for all outstanding shares of Lisata common stock has been extended from April 13, 2026 to May 29, 2026.
- Waiver of Claims: Lisata has agreed not to pursue claims against Parent or Purchaser regarding the failure to commence the offer by the original April 13 date, provided Parent pays the agreed expenses and commences the offer by the new deadline.
- Termination Rights: Lisata retains the right to terminate these waivers if Parent fails to make payments or commits a material breach that is not cured within two business days.
Guidance, Outlook, and Risks
Outlook and Status: The tender offer has not yet commenced. The filing serves as an informational update and is not an offer to purchase shares. Final tender offer materials (Schedule TO) and solicitation statements (Schedule 14D-9) will be filed upon commencement.
Risks and Contingencies: The filing highlights significant risks associated with the transaction and the Company's operations:
- Transaction Completion: Risks that the tender offer may not commence promptly or at all, or that closing conditions may not be satisfied.
- Shareholder Response: Uncertainty regarding the number of shares tendered and the possibility of competing offers.
- Legal and Financial: Potential for stockholder litigation, termination fees, and unanticipated transaction costs.
- Operational Risks: Dependence on the successful clinical development and regulatory approval of product candidates; uncertainties regarding cash sufficiency and runway.
- Employee Retention: Potential difficulties in retaining employees due to the pendency of the transaction.
Investor Verification Checklist
- Verify the final terms of the tender offer in the upcoming Schedule TO and Schedule 14D-9 filings.
- Confirm whether the $1.1 million expense payment has been received by the Company.
- Monitor the May 29, 2026 deadline for the commencement of the tender offer.
- Review the Company's most recent Form 10-K (for the year ended December 31, 2025) for detailed cash runway and liquidity data not included in this 8-K.
- Assess the status of Lisata's clinical trials and regulatory approvals, as these impact the Company's standalone value if the merger fails.